Issue link: http://osercommunicationsgroup.uberflip.com/i/709452
C h a i n D r u g s t o r e D a i l y 8 5 S u n d a y, A u g u s t 7 , 2 0 1 6 manufacturing company. With 70 years of experience, West-Ward has a long- standing presence in the U.S. oral solid generics market, with a focus on quality manufacturing and high service levels. West-Ward is the U.S. operations arm of Hikma, responsible for marketing, planning and distributing products in both the injectable and non-injectable business units. West-Ward is supported by seven FDA-registered manufacturing facilities across the globe, with three based in the U.S. West-Ward has grown at a rate faster than that of the consolidat- ed company, increasing the importance of the U.S. market to Hikma. In 2015 alone, West-Ward represented 48 percent of Hikma's group sales. In 2011, West-Ward became the sec- ond largest injectable supplier by volume in the U.S. after the acquisition of Baxter's Multi-Source Injectables (MSI) division. Continuing the growth of the injectables business, in 2014, Hikma/West-Ward announced the acqui- sition of certain assets of Bedford Laboratories (the generic sterile injecta- bles division of Boehringer Ingelheim), thereby adding to its injectable product portfolio. In combination with the exist- ing portfolio and FDA manufacturing facilities in Portugal and Germany, these acquisitions solidified the portfolio and reinforced West-Ward as a full service generics manufacturer. West-Ward's product portfolio includes more than 60 products in almost 200 dosage forms and strengths, including controlled sub- stances. West-Ward's commitment to growth continued in February 2016, when it acquired Roxane Laboratories, Inc. and Boehringer Ingelheim Roxane Inc. (together "Roxane"), a well-established U.S. specialty generics company with a highly differentiated product portfolio W est-W ard (C o nt'd. fro m p. 1 ) and best-in-class R&D capabilities. This transaction brings together two important players in the generic pharmaceutical market, establishing West-Ward as one of the largest in the U.S. generic market by revenue, and enhancing the already-rich line of products for all patients and stake- holders. The broad non-injectable portfo- lio expanded to more than 100 products in more than 400 dosage forms. Michael Raya, Chief Executive Officer of West-Ward, said of the recent Roxane Laboratories acquisition: "Roxane is highly complementary to our existing U.S. business. Today we are a market leader in generic injectables with a large and increasingly differentiated product portfolio. The acquisition of Roxane will significantly strengthen our non-injectables business, bringing a broad and diversified non-injectables portfolio, strong R&D capabilities and well-invested, state-of-the-art manufac- turing facilities. With this acquisition, we will transform our U.S. operations, becoming the sixth largest U.S. generics provider and ensuring we have the abili- ty to continue our strong trajectory of growth." West-Ward is focused on continuous supply given the span of the global mar- ket shortages across the industry. The recent acquisitions have significantly expanded West-Ward's capacity to pro- duce quality pharmaceuticals in state-of- the art manufacturing facilities. Hikma develops, manufactures and markets a broad range of pharmaceutical products spanning 45 countries across the U.S., Europe, Middle East and North Africa. The business is conducted through three segments: branded, injecta- bles and generics with 27 manufacturing facilities worldwide. Hikma's revenues for the year 2015 exceeded $1.4 billion globally. For more information, visit booth #2009. available. Made in America, factory built precision is guaranteed with the state-of- the-industry 180,000 square foot manu- facturing facility. The millwork team allows customers to design and purchase their products from one location, saving time, consoli- dating communications and most impor- tantly, saving money. The project management team coor- dinates the delivery and installation of the project. Even major room projects install in three to five days – bare floor to occupy in three to five days! Functionality and Style The Uniweb Total Store Solution is based on factory built modular units, allowing for total flexibility of the complete unit and its accessories. Given that it is a cus- tom manufacturer, it is not limited to "fixed" boxes or components. Every U niweb (C o nt'd. fro m p. 4 ) square foot of space will be fully utilized. Uniweb's credentials have proven that it can increase pharmacy inventory capacity by 30 percent and offer project costs 15 to 20 percent less than conven- tional millwork solutions. Add to this the tax advantage of depreciating the complete project as a "fixture" – accel- erates return of investment. Likewise, retail product facings are increased by a minimum of 17 and in some cases up to 50 percent. This extreme capitalization on space results in greater profits for retailers. How is Uniweb responding to key issues impacting retailers? By providing a turnkey, solution proven, retail and pharmacy projects on time and on budg- et. Visit Uniweb at booth #2916. For more information, call 800.486.4932 or go to www.uniwebinc.com. the patients they jointly serve. Specialty Generics Leader Mallinckrodt's Specialty Generics busi- ness developed as an extension of the company's API platform in the mid- 1990s. Today, its Specialty Generics segment includes a robust portfolio of controlled substances for pain manage- ment, substance abuse and attention- deficit hyperactivity disorders. It manu- factures APIs for its products as well as for some of the world's most recognized companies; it is also one of the world's leading producers of bulk acetamino- phen. Mallinckrodt's Specialty Generics business is vertically integrated, enabling internal quality control dur- ing every step of a product's develop- ment. Through its global operations platform, its ability to manufacture complex products and deliver them efficiently to customers reflects Mallinckrodt's core values that have held true since 1867 – quality, integri- ty and service. Investing in the Future The same goal of providing high-quali- ty, innovative products that began almost a century and a half ago with the Mallinckrodt brothers still exists today. Mallinckrodt applies its acquire to Mallinck ro dt (C o nt'd. fro m p. 4 ) invest business model to key product portfolios like Specialty Generics. For example, that business has benefited from a skilled Research and Development (R&D) team. The compa- ny's development pipeline remains focused in areas where it believes it can bring differentiated value to the mar- ketplace, and the Specialty Generics R&D projects are a high priority. The company has also invested millions of dollars in research efforts focusing on exploring the abuse-deterrent potential of its proprietary formulation technolo- gies. Its supply chain organization con- tinues to invest in several infrastructure and capacity improvements, better ensuring consistent delivery of high- quality products. For its Specialty Generics segment and throughout Mallinckrodt, the company remains laser focused on its mission state- ment – Managing Complexity. Improving Lives. Its unique strengths provide the foundation for managing the complexities inherent to specialty pharmaceutical products – particularly controlled sub- stances – and every day it is committed to meeting the needs of patients, delivering value toward improving their lives. Visit Mallinckrodt Pharmaceuticals at booth #171. For more information, call 800.325.8888 or go to www .mallinckrodt.com. NB: Rouses Point Pharmaceuticals has been in business for six years and is headquartered in Bonita Springs, Florida. Our product line includes both generics and brands. CDD: What would you say makes your company unique? NB: Rouses Point Pharmaceuticals has the unique advantage of flexibility, which allows us to respond quickly to the needs of our customers. We are a small, well organized company that is structured effi- ciently. We have a company-wide focus on customer service, fast turn-around on decisions and a positive attitude. CDD: What are you doing this year that's different from what you did last year? NB: This year we are focusing on expanding our product line and partner- ing with our sister companies to co-pro- mote products. As a result, the company will be growing with personnel and we will have a greater variety of products to offer our customers. CDD: Where is your current product emphasis and are you introducing any new products? NB: Our product emphasis in on pharma- ceuticals, be it brands or generics. In addition to the generic products we offer, we have begun a co-promotional initia- tive with Akrimax, a sister company, to market InnoPran XL – a unique brand product that is not substitutable and has particular formulation benefits. CDD: What are your customer service levels? NB: We are proud to say that we have excellent customer service levels – between 98 percent and 100 percent. We mean it R o uses Po int (C o nt'd. fro m p. 1 ) when we say 'We do business the old-fash- ioned way – We Deliver.' Our consistent focus on customer service has been a major part of our success. This was recognized by Cardinal who awarded us their Quality Service Award for the past two years. CDD: What is your outlook for the next year? NB: We are expecting a new product approval at the end of this year, as well as proceeding with some major acquisitions that will make next year a time of renewed growth for us and our customers. CDD: To what do you attribute your company's success? NB: Rouses Point has a very unique exec- utive leadership team that is highly expe- rienced with an enthusiastic 'can-do' atti- tude and excellent problem-solving skills. You know what is the best part of being at Rouses Point? We all really like working together and our professional and positive camaraderie influences the rest of the company. We believe enthusiasm breeds success that starts internally and projects outward to our customers, partnerships and product offerings. CDD: How do potential new customers know that they can trust you with their business? NB: Trust is built on relationships with peo- ple who are experienced and have longevi- ty in the business. Our leadership team cer- tainly has experience and longevity, and very solid relationships with a trustworthy reputation. We would encourage any poten- tial new customers to simply refer to our current long-standing customers to consider building a new relationship with us. Visit Rouses Point Pharmaceuticals at booth #1108. For more information, call 866.931.0712 or go to www.rouses pointrx.com.